ADAS 3D LA
Left atrium fibrotic substrate analysis for EP procedures
Software · On PremiseCompany source
Company profile
About Adas3D Medical S.L
Adas3D Medical S.L. is a Barcelona-based medical imaging software company specializing in electrophysiology (EP) applications. The company emerged in 2013 from Universitat Pompeu Fabra and is the recent offspring of the electrophysiology business of Galgo Medical. Adas3D develops advanced post-processing software solutions that enable electrophysiologists to extract critical clinical information from cardiac MRI and CT imaging. Their flagship products, ADAS 3D LV and ADAS 3D LA, analyze fibrotic tissue in the left ventricle and left atrium respectively, helping physicians plan treatment approaches, guide catheter ablation procedures, and monitor patient outcomes. The software quantifies and visualizes cardiac fibrosis, generates detailed 3D anatomical models, and can be imported into catheter navigation systems to serve as a roadmap during interventions. Developed in close cooperation with key opinion leaders in electrophysiology, the platform is based on clinical evidence and designed to support decision-making before, during, and after EP procedures. The company's mission is to improve the prognosis of cardiovascular patients with arrhythmias by expanding the accessibility and use of cardiac imaging in electrophysiology procedures. With AI-powered automated segmentation capabilities coming soon, Adas3D aims to remain at the forefront of technological advancement in the EP field.
Company description Adas3D Medical S.L official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Work at Adas3D Medical S.L?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Atrial fibrillation
- Cardiac arrhythmias
- Ventricular arrhythmias requiring catheter ablation
Who it serves
- Cardiologists
- Electrophysiologists
- EP labs
- Health systems
Deployment & integration
On Premise deployment with recorded integration context.
Recorded integration context: Catheter navigation systems for electroanatomical mapping.
Geographic context
MarketsEurope · Global · USA (with limitations on post-procedure features)
Company sourceOfficial website
Company milestones
Platform expansion
AI-powered automated segmentation coming soon in next release. ISO certification obtained.
Partnerships
Recorded partners
- Universities worldwide including Johns Hopkins
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ADAS 3D LV
MRI-based left ventricle fibrosis analysis with CT anatomy visualization
Software · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Ventricular tachycardia substrate mapping with cardiac computed tomography and cardiac magnetic resonance imaging: Head-to-head comparison of two clinically available postprocessing platforms.Heart rhythm · Mar 1, 2026
Comparing two commercially available postprocessing tools for atrial 3D LGE quantification in patients with atrial fibrillation.Heart rhythm · Dec 1, 2025
Optimizing ventricular tachycardia ablation through imaging-based assessment of arrhythmic substrate: A comprehensive review and roadmap for the future.Heart rhythm O2 · Aug 1, 2024
Post-Ablation cardiac Magnetic resonance to assess Ventricular Tachycardia recurrence (PAM-VT study).European heart journal. Cardiovascular Imaging · Jan 29, 2024
Scar conducting channel characterization to predict arrhythmogenicity during ventricular tachycardia ablation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · Mar 30, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
ADAS 3DK240791 · 510k · Sep 9, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Fibrosis quantification and visualization
In left ventricle and left atrium myocardium
Treatment planning support
Pre-procedural decision making for EP interventions
Procedural guidance
Roadmap integration with catheter navigation systems
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Luis Serra
President
Antoni Riu
Managing Director
Xavi Planes
Chief Technology Officer
Jacobo Gil de Biedma
Business Development Director
Francia Rojas
Quality and Regulatory Affairs Director
06 · Company updates
Updates from Adas3D Medical S.L
Recent articles published on Adas3D Medical S.L's official website.
Publications
Read on Adas3D Medical S.LImaging Integration in VT Ablation Takes the Spotlight: ADAS3D Medical at VT Symposium 2025
Read on Adas3D Medical S.LADAS3D Medical Secures Chinese NMPA Approval for Software Distribution
Read on Adas3D Medical S.LCardiac MRI Post Processing Software: Innovations to Improve Cardiac Diagnostics
Read on Adas3D Medical S.LChallenging case of recurrent Ventricular Tachycardia
Read on Adas3D Medical S.L07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.